Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability

Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

(2014) Marlo Blazer et al.   ANNALS OF SURGICAL ONCOLOGY

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

(2014) L. Marthey et al.   ANNALS OF SURGICAL ONCOLOGY

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

(2013) Somnath Mukherjee et al.   LANCET ONCOLOGY

Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma

(2013) Hemchandra Mahaseth et al.   PANCREAS

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

(2012) Peter J Hosein et al.   BMC CANCER

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer

(2012) Francesco Leone et al.   CANCER

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

(2012) Sophie Gourgou-Bourgade et al.   JOURNAL OF CLINICAL ONCOLOGY

Malnutrition and pancreatic surgery: Prevalence and outcomes

(2012) Marco La Torre et al.   JOURNAL OF SURGICAL ONCOLOGY

Resection after neoadjuvant therapy for locally advanced, “unresectable” pancreatic cancer

(2012) Oliver Strobel et al.   SURGERY

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

(2011) Patrick J. Loehrer et al.   JOURNAL OF CLINICAL ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE